Titanium Dioxide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Titanium dioxide: From an Unspecified Topical Use to Drug-Induced Osteoporosis
One-Sentence Summary
Titanium dioxide is an inert pigment and UV-blocking agent. In Singapore it is registered as a single-ingredient ointment, but no approved indication is recorded. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but 0 clinical trials and 0 publications support this prediction. The evidence is a model prediction only, so this is a low-confidence signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the Singapore license data |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Titanium dioxide is known as an inert pigment and sunscreen/UV-blocking agent. It is not used as a drug that acts on bone metabolism.
No pharmacological link between titanium dioxide and drug-induced osteoporosis has been identified. Titanium is used in bone implants, but that is a biomaterial and device application, not a drug effect on osteoporosis. The high TxGNN score most likely reflects graph-based similarity rather than a biological mechanism. It should not be read as evidence of efficacy.
The other predictions (ranks 2 to 10) are mostly diabetic retinopathy and various cataract types. They share the same weakness. The retrieved literature for diabetic retinopathy covers analytical and imaging uses of TiO2, such as extracellular vesicle purification, a retinal oximetry phantom and fluorescein conjugates for angiography. None of it shows a treatment effect. TiO2 is also photoreactive and can generate reactive oxygen species under UV light, which argues against a protective role in the lens. Nanoparticle toxicity is an additional concern for any ocular use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16547P | VEELANZ'S OINTMENT | Ointment | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone. There are no clinical trials, no supporting literature and no plausible pharmacological mechanism. Titanium dioxide is an inert topical agent. The other top-ranked predictions are also at L5, so none justifies advancing.
To proceed, the following is needed:
- Mechanism of action data, and a credible biological rationale linking titanium dioxide to bone metabolism
- Package insert warnings and contraindications from the Singapore regulator (HSA), which are needed before any safety screening
- The approved indication of the registered ointment, to establish the original use
- Preclinical or clinical studies showing a therapeutic effect on drug-induced osteoporosis
- A route compatibility assessment, since the only registered form is a topical ointment and a systemic bone indication would need a different route
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.